Amy S. Shah, MD, MS

Newly diagnosed type 2 diabetes has steadily risen by 4%-5% annually in the United States over the past 20 years; However, during the first year of the pandemic, the Journal of Pediatrics reported a possible 77% increase in youth-reported cases. Coupled with nearly 1 in 3 children being overweight, treatment for this patient population has recently evolved. 

Dr Amy S. Shah of the Cincinnati Children's Hospital Medical Center reports on the current therapeutic and lifestyle modifications guidelines for this patient population, including the consideration of prescribing glucagon-like peptide 1 receptor agonists such as liraglutide, dulaglutide, and exenatide.

--

Amy S. Shah, MD, MS, Professor of Pediatrics, Division of Endocrinology, Director of the Adolescents Type 2 Diabetes Program, Cincinnati Children's Hospital Medical Center, The University of Cincinnati, Cincinnati, Ohio

Amy S. Shah, MD, MS, has disclosed the following relevant financial relationships:

Received research grant from: National Institutes of Health

Received income in an amount equal to or greater than $250 from: Journal of the American Medical Association (Associate Editor)

Newly diagnosed type 2 diabetes has steadily risen by 4%-5% annually in the United States over the past 20 years; However, during the first year of the pandemic, the Journal of Pediatrics reported a possible 77% increase in youth-reported cases. Coupled with nearly 1 in 3 children being overweight, treatment for this patient population has recently evolved. 

Dr Amy S. Shah of the Cincinnati Children's Hospital Medical Center reports on the current therapeutic and lifestyle modifications guidelines for this patient population, including the consideration of prescribing glucagon-like peptide 1 receptor agonists such as liraglutide, dulaglutide, and exenatide.

--

Amy S. Shah, MD, MS, Professor of Pediatrics, Division of Endocrinology, Director of the Adolescents Type 2 Diabetes Program, Cincinnati Children's Hospital Medical Center, The University of Cincinnati, Cincinnati, Ohio

Amy S. Shah, MD, MS, has disclosed the following relevant financial relationships:

Received research grant from: National Institutes of Health

Received income in an amount equal to or greater than $250 from: Journal of the American Medical Association (Associate Editor)

Newly diagnosed type 2 diabetes has steadily risen by 4%-5% annually in the United States over the past 20 years; However, during the first year of the pandemic, the Journal of Pediatrics reported a possible 77% increase in youth-reported cases. Coupled with nearly 1 in 3 children being overweight, treatment for this patient population has recently evolved. 

Dr Amy S. Shah of the Cincinnati Children's Hospital Medical Center reports on the current therapeutic and lifestyle modifications guidelines for this patient population, including the consideration of prescribing glucagon-like peptide 1 receptor agonists such as liraglutide, dulaglutide, and exenatide.

--

Amy S. Shah, MD, MS, Professor of Pediatrics, Division of Endocrinology, Director of the Adolescents Type 2 Diabetes Program, Cincinnati Children's Hospital Medical Center, The University of Cincinnati, Cincinnati, Ohio

Amy S. Shah, MD, MS, has disclosed the following relevant financial relationships:

Received research grant from: National Institutes of Health

Received income in an amount equal to or greater than $250 from: Journal of the American Medical Association (Associate Editor)